Resultados de la búsqueda 61-70 of 234 for Vijay Singh

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Jacksonville, Fla. The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Jacksonville, Fla. The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B ...

  3. Neurología - Ensayos clínicos - Mayo Clinic

    VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Jacksonville, Fla. The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Jacksonville, Fla. The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B ...

  6. Cirugía - Médicos - Mayo Clinic

    Vijay Shah, M.D.. gastroenterólogo; Hepatólogo del trasplante. Rochester, MN ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by ...

  9. Neurología - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    In the study, 122 patients will be randomized in a 1:1 ratio to receive doxorubicin treatment (Arm 1) or L19TNF treatment in combination with doxorubicin (Arm 2) ...